Bajaj Healthcare Peer Comparison

NSE: BAJAJHCARE | BSE: 539872

₹315.20

₹4.50 (1.45%)

As on 08-Nov-2026IST

Market cap

₹1,059 Cr

Revenue (TTM)

₹656 Cr

P/E Ratio

42.4

P/B Ratio

1.9

Div. Yield

0.5 %

Edit

	Bajaj Healthcare	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Market cap (₹ Cr)	1,059	43,303	25,502	19,167	13,675
Revenue (₹ Cr)	656	10,234	2,307	2,684	710
Net Profit (₹ Cr)	20.61	1,092.67	452.55	669.74	188.64
Net Margin (%)	3.77	10.67	19.31	24.24	25.69
RoE (%)	11.28	21.65	23.18	19.79	20.46
Price to Earnings	42.43	39.60	56.35	28.62	72.61
Price-To-Book	1.90	8.10	12.57	5.28	14.28

Income Statement (₹ Cr)

	Bajaj Healthcare	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Operating Revenue	655.82	10,234.10	2,307.19	2,684.41	709.64
Total Income	662.12	10,245.27	2,343.69	2,763.43	734.34
Total Expenditure	542.50	8,141.47	1,602.28	1,761.70	458.93
EBITDA	113.32	2,092.63	704.92	922.70	250.72
Depreciation	29.49	430.12	104.34	82.27	17.12
EBIT	83.83	1,662.51	600.57	840.44	233.59
Interest	23.52	151.49	28.27	5.42	8.49
Other Income	6.31	11.17	36.50	79.02	24.69
Exceptional Items	-33.25	-27.85	0.00	-25.66	0.00
Profit before Tax	33.37	1,494.35	608.80	888.39	249.79
Provision for Tax	8.41	401.68	156.25	218.65	61.16
Profit after Tax	24.96	1,092.67	452.55	669.74	188.64

	Bajaj Healthcare	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Shareholder's Funds	557.16	5,344.04	2,029.71	3,631.29	957.32
Minority Interest	0.00	0.82	0.00	0.00	-0.30
Non-Current Liabilities	99.59	980.81	381.27	146.95	106.92
Current Liabilities	324.40	3,838.93	618.58	563.70	248.88
Total Liabilities	923.22	9,514.48	2,930.14	4,157.10	1,174.38

	Bajaj Healthcare	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Non-Current Assets	249.46	3,542.74	1,471.67	1,454.42	534.87
Current Assets	572.28	6,027.59	1,389.85	2,864.85	723.33
Total Assets	923.22	9,514.48	2,930.14	4,157.10	1,174.38
Total Debt*	233.46	1,204.08	196.61	0.00	148.29
Net Current Assets	247.88	2,188.66	771.28	2,301.15	474.44
Contingent Liabilities	23.56	258.92	13.18	4.82	--

	Bajaj Healthcare	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Cash From Operating Activities	58.08	943.55	346.68	565.41	69.55
Cash Flow from Investing Activities	-47.78	-1,193.06	-423.73	-570.15	-330.93
Cash from Financing Activities	24.33	343.43	20.98	-64.34	247.29
Net Cash Inflow / Outflow	34.63	93.92	-56.08	-69.08	-14.09

	Bajaj Healthcare	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
ROCE (%)	7.04	25.25	27.50	24.61	28.50
ROE (%)	11.28	21.65	23.18	19.79	20.46
ROA (%)	2.74	11.17	16.27	16.78	16.29
EBIT Margin (%)	12.78	16.24	26.03	31.31	32.92
Net Margin (%)	3.77	10.67	19.31	24.24	25.69
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Bajaj Healthcare	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Revenue Growth (%)	14.25	21.12	50.46	8.19	26.57
EBIT Growth (%)	45.14	32.84	138.53	24.77	26.37
Net Profit Growth (%)	-51.23	33.33	88.45	26.27	24.97
EPS Growth (%)	14.62	38.63	131.13	29.79	8.48
Book Value Growth (%)	18.59	11.36	22.95	18.43	79.97

	Bajaj Healthcare	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Price / Earnings	16.93	38.85	56.35	27.76	72.61
Price / Book Value	1.90	8.10	12.57	5.28	14.28
Dividend Yield (%)	0.48	0.16	0.17	0.32	0.12
EV/EBITDA	11.07	21.20	35.95	19.92	54.68
Market Cap (₹ Cr)	975.39	30,257.56	15,412.11	11,956.86	6,690.53

	Bajaj Healthcare	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Debt to Equity	0.13	0.10	0.10	0.00	0.07
Short term debt to equity ratio	0.31	0.16	--	--	0.12
Current Ratio	1.76	1.57	2.25	5.08	2.91
Quick Ratio	1.03	0.92	1.35	3.69	1.80
Interest Coverage	2.42	10.86	22.53	165.03	30.42

	Bajaj Healthcare	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Debtors to sales (%)	38.37	26.69	12.76	36.81	34.68
Asset Turnover	0.72	1.05	0.83	0.67	0.61
Receivable days	145.02	88.68	77.32	144.58	115.16
Inventory Days	112.87	84.11	80.83	96.67	96.15
Payable days	124.08	176.65	125.94	135.45	106.08
Cash Conversion Cycle	133.80	-3.86	32.22	105.80	105.23

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.